An abstract was recently published on the Health Affairs website title, “Greater Adherence To Diabetes Drugs Is Linked To Less Hospital Use And Could Save Nearly $5 Billion Annually”.  The abstract, written by Ashish K. Jha, an associate professor of health policy at the Harvard School of Public Health and an associate professor of medicine at Harvard Medical School, et al. offers commentary on the substantial benefits of improving adherence to medication for both reducing costs and Read More

Cardium Therapeutics (NYSE MKT: CXM) has released new case study information on its Excellagen wound care management product. Excellagen is a new, highly-refined bovine Type I collagen–based topical gel designed to support favorable wound care management. Excellagen’s unique high molecular weight sterile, collagen formulation is topically applied through easy to control, pre-filled, single-use syringes. It is recommended that Excellagen be applied Read More

An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix (OTCBB: CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker. Read More

ALR Technologies Updates Shareholders on Commercial Launch of Diabetes Management System

ALR Technologies Inc. (OTCBB: ALRT) (the “Company”), a health information technology company, is pleased to provide shareholders with an update for its FDA-cleared Health-e-Connect System (“the System”) for remote monitoring and chronic disease management. Read More

Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017.  A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.”  With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More

It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More

In their latest interview, www.ceocfointerviews.com spent some time with Cardium Therapeutics (NYSE MKT: CXM) CEO and Chairman Christopher J. Reinhard.  The article title, “With their Regenerative Medicine Product Generx® for Coronary Artery Disease in Phase 3 Registration Study for International Markets, Cardium Therapeutics Inc. is Leading the Evolution of a Revolution” can be seen on the CEO/CFO Interviews website at: Read More

Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics. Read More

Recently, an article by Rex Graham was published on SanDiegoBiotechnology.com discussing Cardium Therapeutics (NYSE MKT: CXM).

An excerpt from the article: Read More

Cardium Therapeuitcs (NYSE MKT: CXM) is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to partnering, commercialization and other economic monetizations. Cardium’s investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing and cardiovascular Read More